Arbekacin inhalation

Drug Profile

Arbekacin inhalation

Alternative Names: ME-1100

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Meiji Seika Pharma
  • Developer Keio University School of Medicine; Meiji Seika Pharma
  • Class Aminoglycosides; Antibacterials; Cyclohexanols; Cyclohexylamines; Hexosamines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Nosocomial pneumonia
  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in Japan (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 02 Jun 2015 Arbekacin inhalation receives Fast Track designation for Nosocomial pneumonia [Inhalation,Aerosol] (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top